Weight-loss drugs are so popular they’re headed for Medicare negotiations
Lilly’s Trulicity and Novo Nordisk’s Ozempic have rocketed into Medicare’s top-10 spending list. That sets them up to be subject to price negotiations — soon.
View original article
Contributor: Renuka Rayasam, McKenzie Beard
